ChemoCentryx, Inc.Mountain View, CA United States
Company Description
The nucleus of ChemoCentryx's research is molecular cell secretions. The drug developer focuses on orally administered drugs targeting the body's chemokine system, a molecular network that regulates inflammatory and immune responses. Its lead candidate in clinical development is Traficet-EN, a potential treatment for Crohn's disease. ChemoCentryx is researching other compounds that could treat type 2 diabetes and a form of brain cancer. Its R&D activities for Traficet-EN are being done in collaboration with
| 850 Maude Ave. | Phone: 650-210-2900 | http://www.chemocentryx.com |
| Mountain View, CA 94043 | Fax: 650-210-2910 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
ChemoCentryx, Inc. Rankings
Executives
| 11 executives listed for ChemoCentryx, Inc.'s Mountain View, CA location. | ||
| President, CEO, and Director | Thomas Schall | |
|---|---|---|
| SVP Finance, CFO, and Secretary | Susan Kanaya | |
| SVP Drug Discovery and Chief Scientific Officer | Juan Jaen | |
Financials
| Company Type | Public - NASDAQ: CCXI Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 64 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on ChemoCentryx, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
